| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357535 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
| US9655946 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
Daptomycin is owned by Hospira.
Daptomycin contains Daptomycin.
Daptomycin has a total of 2 drug patents out of which 0 drug patents have expired.
Daptomycin was authorised for market use on 21 June, 2021.
Daptomycin is available in powder;intravenous dosage forms.
Daptomycin can be used as treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18, treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12.
The generics of Daptomycin are possible to be released after 11 September, 2033.
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...
Dosage: POWDER;INTRAVENOUS
DAPTOMYCIN family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759497 | XELLIA PHARMS APS | Daptomycin formulations |
Aug, 2038
(14 years from now) | |
Daptomycin is owned by Xellia Pharms Aps.
Daptomycin contains Daptomycin.
Daptomycin has a total of 1 drug patent out of which 0 drug patents have expired.
Daptomycin was authorised for market use on 30 January, 2023.
Daptomycin is available in powder;intravenous dosage forms.
The generics of Daptomycin are possible to be released after 28 August, 2038.
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 30 January, 2023
Treatment: NA
Dosage: POWDER;INTRAVENOUS
DAPTOMYCIN family patents